Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27650829
PubMed Central
PMC5093200
DOI
10.1007/s00277-016-2802-z
PII: 10.1007/s00277-016-2802-z
Knihovny.cz E-zdroje
- Klíčová slova
- Allogeneic hematopoietic stem cell transplantation, Allogeneic stem cell transplantation, Comorbidity, Iron overload, Myelodysplastic syndromes, Prognosis, Red blood cell transfusion,
- MeSH
- dospělí MeSH
- homologní transplantace mortalita trendy MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mortalita trendy MeSH
- myelodysplastické syndromy diagnóza mortalita terapie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk mortalita trendy MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS). However, patient cohorts are often heterogeneous by disease stage and treatment modalities, which complicates interpretation of the results. This study aimed to obtain a homogeneous patient cohort by including only de novo MDS patients who received upfront allogeneic SCT after standard high dose myelo-ablative conditioning. The effect of pre-transplant factors such as age, disease stage, transfusions, iron parameters and comorbidity on overall survival (OS), non-relapse mortality (NRM), and relapse incidence (RI) was evaluated in 201 patients. In this cohort, characterized by low comorbidity and a short interval between diagnosis and transplantation, NRM was the most determinant factor for survival after SCT (47 % after 2-year follow-up). WHO classification and transfusion burden were the only modalities with a significant impact on overall survival after SCT. Estimated hazard ratios (HR) showed a strongly increased risk of death, NRM and RI, in patients with a high transfusion-burden (HR 1.99; P = 0.006, HR of 1.89; P = 0.03 and HR 2.67; P = 0.03). The HR's for ferritin level and comorbidity were not significantly increased.
Chaim Sheba Medical Center Tel Hashomer Israel
Deutsche Klinik fur Diagnostik and KMT Wiesbaden Germany
Evangelismos Hospital Athens Greece
Helsinki University Central Hospital Helsinki Finland
Institute of Hematology and Blood Transfusion Prague Czech Republic
Leiden University Medical Center Leiden The Netherlands
Radboud University Medical Centre Nijmegen The Netherlands
Universitatsklinikum Dresden Dresden Germany
University Hospital Eppendorf Hamburg Germany
University Hospital Essen Germany
Zobrazit více v PubMed
Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–538. doi: 10.1056/NEJMp048266. PubMed DOI
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585. doi: 10.1182/blood-2004-01-0338. PubMed DOI
Wong FL, Francisco L, Togawa K, et al. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns. Blood. 2010;115:2508–2519. doi: 10.1182/blood-2009-06-225631. PubMed DOI PMC
Alessandrino EP, la Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95:476–484. doi: 10.3324/haematol.2009.011429. PubMed DOI PMC
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. PubMed
Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603. doi: 10.1200/JCO.2005.01.7038. PubMed DOI
Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–881. doi: 10.1182/blood-2014-03-563221. PubMed DOI PMC
Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90:1–10. doi: 10.1007/s00277-010-1091-1. PubMed DOI
Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114:5251–5255. doi: 10.1182/blood-2009-07-234062. PubMed DOI
Sahlstedt L, Ebeling F, von Bonsdorff L, et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol. 2001;113:836–838. doi: 10.1046/j.1365-2141.2001.02820.x. PubMed DOI
Durken M, Herrnring C, Finckh B, et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med. 2000;28:887–894. doi: 10.1016/S0891-5849(00)00174-X. PubMed DOI
Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586–4588. doi: 10.1182/blood-2006-10-054924. PubMed DOI PMC
Bazuaye GN, Buser A, Gerull S, et al. Prognostic impact of iron parameters in patients undergoing allo-SCT. Bone Marrow Transplant. 2012;47:60–64. doi: 10.1038/bmt.2011.13. PubMed DOI
Platzbecker U, Bornhauser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) Biol Blood Marrow Transplant. 2008;14:1217–1225. doi: 10.1016/j.bbmt.2008.08.006. PubMed DOI PMC
Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42:799–805. doi: 10.1038/bmt.2008.262. PubMed DOI
Armand P, Sainvil MM, Kim HT, et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013;48:146–147. doi: 10.1038/bmt.2012.94. PubMed DOI PMC
Pullarkat V (2010) Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol. 2010:1–12 PubMed PMC
Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001. doi: 10.1002/cncr.23375. PubMed DOI
de W, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol. 2000;110:620–630. doi: 10.1046/j.1365-2141.2000.02200.x. PubMed DOI
Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749–756. doi: 10.1038/bmt.2011.110. PubMed DOI
Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249–3256. doi: 10.1200/JCO.2013.53.8157. PubMed DOI PMC
Martino R, de Wreede L, Fiocco M, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant. 2013;48:761–770. doi: 10.1038/bmt.2012.236. PubMed DOI
Luger SM, Ringden O, Zhang MJ, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47:203–211. doi: 10.1038/bmt.2011.69. PubMed DOI PMC
Giralt SA, Horowitz M, Weisdorf D, Cutler C. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol. 2011;29:566–572. doi: 10.1200/JCO.2010.32.1919. PubMed DOI PMC
Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19:396–401. doi: 10.1038/sj.leu.2403640. PubMed DOI
Pereira A, Nomdedeu M, Aguilar JL, et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol. 2011;86:245–250. doi: 10.1002/ajh.21959. PubMed DOI
Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001;97:1180–1195. doi: 10.1182/blood.V97.5.1180. PubMed DOI
Hod EA, Zhang N, Sokol SA, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood. 2010;115:4284–4292. doi: 10.1182/blood-2009-10-245001. PubMed DOI PMC
Sivgin S, Eser B, Bahcebasi S, et al. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT) Ann Hematol. 2012;91:743–749. doi: 10.1007/s00277-011-1358-1. PubMed DOI
